Soleno Granted Patent Covering Potential Oral Treatment, DCCR, Now in Phase 3 Study in Patients
Soleno Therapeutics announced the awarding of a patent for diazoxide choline controlled-release (DCCR) tablets, the company’s investigational therapy for Prader-Willi syndrome (PWS) being evaluated in a new Phase 3 trial. The patent covers “pharmaceutical formulations of diazoxide and diazoxide choline” to treat patients with poor lean body mass and a lean…